This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Ocugen, Inc.
5/9/2025
Good morning and welcome to Oxygen's first quarter 2025 financial results and business update. Please note that this call is being recorded at this time. All participant lines are in listen-only mode. Following the speaker's commentary, there will be a question and answer session. I will now turn the call over to Tiffany Hamilton, Oxygen's Head of Corporate Communications. You may begin.
Thank you, Operator, and good morning, everyone.
Joining me on today's call and webcast is Dr. Shankar Musunari, Occitans chairman, CEO, and co-founder, who will provide a business update and an overview of our clinical and operational progress. Ramesh Ramachandran, our chief accounting officer, is also on the call to provide a financial update for the quarter ended March 31st, 2025. Dr. Huma Kumar, our chief medical officer, will be available to answer questions following the presentation. This morning, we issued a press release detailing associated business and operational highlights for the first quarter of 2025. We encourage listeners to review the press release, which is available on our website at Ockingen.com. This call is being recorded, and a replay with the accompanying slide presentation will be available on the investor section of our website for approximately 45 days. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. which are subject to risks and uncertainties. We may, in some cases, use terms such as predicts, believe, potential, proposed, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements include but are not limited to statements regarding our clinical development activities and related anticipated timelines. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filing with the Securities and Exchange Commission, the SEC, including the risk factors described in the section entitled Risk Factors in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this presentation speak only to the date of the presentation. Except it's required by law, we assume no obligation to update forward-looking statements contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation. Finally, APUTA's quarterly report on Form 10-Q, covering the first quarter of 2025, was filed today. I will now turn the call to Dr. Musunari.
You're reading a preview of the OCGN Q1 2025 earnings call.
Free account.